Semaglutide peptide therapy — Peptide Medicine NY
A diabetes medicine acquired several further clinical uses. The trials are more interesting when each new question remains visible.
From diabetes to further indications
Semaglutide mimics GLP-1, a gut hormone, and was developed as a long-acting treatment for type 2 diabetes. Its approved uses now span type 2 diabetes, chronic weight management, cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity, and MASH, a form of fatty liver disease. Those uses concern particular formulations and eligible populations.
I see why “semaglutide peptide treatment” serves as an umbrella for all of this. Yet the history gains something when the individual trials stay visible. The early cardiovascular trial in type 2 diabetes and the later SELECT trial in people without diabetes asked related questions in different populations. Extending the use involved new evidence, rather than a simple change of wording.
Semaglutide peptide benefits for weight
The STEP 1 randomized trial enrolled 1,961 adults with overweight or obesity without diabetes. Mean body-weight reduction at 68 weeks was 14.9% with semaglutide, versus 2.4% with placebo. That remains a substantial result even alongside newer treatments.
In the 72-week head-to-head obesity trial involving 751 adults, mean weight reduction was 20.2% with tirzepatide and 13.7% with semaglutide (P<0.001). The semaglutide figure here differs from STEP 1 because it comes from another trial. I refuse to assemble a flattering number from each study into a race that nobody ran.
The practical limits deserve room too. Gastrointestinal intolerance can lead people to stop, and substantial weight regain after discontinuation is documented in the research record. The safety review describes the burdens that accompany the efficacy findings.
SELECT, FLOW and SUSTAIN-6
In SELECT, 17,604 adults had established cardiovascular disease and overweight or obesity, without diabetes. Semaglutide reduced the combined outcome of cardiovascular death, nonfatal heart attack or nonfatal stroke by 20% relative to placebo (HR 0.80). This was a relative reduction in that composite outcome in that population.
In FLOW, 3,533 adults had type 2 diabetes and chronic kidney disease. The primary composite included kidney failure, a decline of at least 50% in estimated kidney filtration, or death from kidney or cardiovascular causes. Its hazard ratio was 0.76, corresponding to a 24% lower risk relative to placebo. Naming the actual events makes FLOW’s composite concrete; “kidney protection” is a much looser description.
The earlier SUSTAIN-6 trial involved 3,297 adults with type 2 diabetes at high cardiovascular risk. The cardiovascular composite had HR 0.74, while diabetic-retinopathy complications were more frequent (HR 1.76). The favourable cardiovascular result and the eye complication signal came from the same study.
GLP-1 engineering and appetite
Semaglutide’s chemistry protects it against rapid enzymatic breakdown and encourages reversible binding to albumin, the abundant blood protein, extending its half-life to roughly a week. It promotes glucose-dependent insulin release, suppresses inappropriate glucagon release and slows stomach emptying. The safety review connects its pharmacology with the gastrointestinal effects that can limit treatment.
The brain-pathway experiments in mice and rats found reduced food intake and altered food preference without decreased energy expenditure. That is animal mechanism work. Human descriptions of quieter “food noise” are anecdotal accounts; those descriptions cannot establish which brain pathway produced a particular person’s experience.
Reported effects, cautions & safety
Patient-review sites and research communities describe a consistent pattern. These accounts are anecdotal, not clinical evidence — drawn from drug-review sites and forums, not controlled studies.
Reported benefits: a quieting of food-related thoughts within the first week or two; sharply reduced cravings for sugar and fried food; steady weight loss over months, usually tied to simply eating less; and, in people with diabetes, improved blood-sugar readings. A widely discussed secondary effect is reduced interest in drinking alcohol.
Reported downsides: nausea is the dominant complaint, worst in the first weeks and after dose increases; distinctive sulfur-smelling burps come up more often than official lists suggest; constipation and diarrhea, sometimes alternating; acid reflux; early fatigue on injection day; and, in a smaller group, hair shedding tied to the pace of weight loss rather than the drug itself.
What the clinical record actually flags: GI intolerance during dose escalation is the leading cause of discontinuation, and it is the drug's mechanism at work, not a rare reaction [20]. A boxed warning for thyroid C-cell tumors comes from rodent data; no confirmed human signal exists, but a personal or family history of medullary thyroid cancer or MEN-2 is a contraindication [20]. Gallbladder disease risk is genuinely increased, mostly attributed to the pace of weight loss itself [20]. Rapid blood-sugar correction can worsen existing diabetic retinopathy [20][22]. Substantial weight regain is documented after stopping — this is framed as chronic therapy, not a cure.
Given that risk profile, Promise Peptides (mypromise.com) prescribes semaglutide only after its licensed U.S. clinician assesses the request; that assessment can end without a prescription. Its patients must be in the U.S., and both their state and the treatment under consideration limit its options.
Treatment and product form
Semaglutide has FDA-approved medicines; a product made by compounding has no FDA approval. Results for a studied formulation cannot verify the identity, preparation or suitability of every product carrying the compound’s name. The clinical safety literature supplies a risk discussion for semaglutide; an individual prescribing decision requires clinical assessment.
A new, appropriate human trial is the expansion of this medicine’s role I respect most. Retatrutide is a separate engineered molecule with an earlier clinical record, and GHK-Cu has a largely topical literature. The phrase “peptide therapy” can bring them into the same search, while leaving the evidence for each very different.